

PATENT ATTORNEY DOCKET NO.: 056291-5170

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	Application of: Andrew BAXTER et al.	)		
Applic	eation No.: 10/501,510 V	)	Group Art U	Jnit: <b>1615</b>
Filed:	May 25, 2005	)	Examiner:	Unassigned
For:	N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES	)		

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

## Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Examiner's	Inventor	U.S. Serial No.	U.S. Patent No.	PCT Publication No.
Initials		Filing Date	Issue Date	PCT Publication Date
5165	Baxter et al.	10/499,102		WO 03/051870 A1
100592		November 23, 2004		June 26, 2003

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

<u>PLEASE DO NOT PRINT</u> the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

## **Citation of Documents**

Attached is a Form PTO-1449 listing the enclosed foreign patent and literature documents.

Several of these references were cited in an International Search Report dated April 24, 2003 in the corresponding PCT application from which the above-identified application is a U.S. national stage application. A copy of that International Search Report was filed in the aboveidentified application on July 15, 2004. The U.S. Patent and Trademark Office has not confirmed receipt of the references cited in the International search Report.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5170 and proceed to consider this IDS.

2

ATTORNEY DOCKET NO.: 056291-5170

Application No.: 10/501,510

Page 3

This Information Disclosure Statement is intended to be in full compliance with the rules,

but should the Examiner find any part of its required content to have been omitted, prompt notice

to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable

Applicant to fully comply.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith

filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with

an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby

authorized by this paper to charge any additional fees during the entire pendency of this

application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required,

including any required extension of time fees, or credit any overpayment to Deposit Account No.

50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR

By

**EXTENSION OF TIME** -in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bockius LLP

Date: October 13, 2005

Morgan Lewis & Bockius LLP

Customer No. 009629 1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

DJB:mk

Tel. No.: 202-739-3000

Registration No. 25,323 Tel. No.: (202) 739-5320

Donald J. Bird

Fax No.: (202) 739-3001

			Attorney Docket No.		Application No. 10/501,510				
INFOR	THE RESERVE OF THE PERSON NAMED IN	TION DISCLOSUI		056291-5170		` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `			
(Use several sheets if necessary)			Applicants: Andrew BAXTER et al.		PAGE 1 of 1				
	PTO Form 1449		OCT 1 3 2005	Filing Date: May 25, 2005		Group Art Unit: 1615			
Initial Document No. Name Class Sub-Class Filing Date  1 2002/01/43024 A 1 October 3 2002 Murragean et al. 514 258 1 December 14 2000									
Initial		Document No.	MADENTE	Name	Class	Sub-Class	Filing Date		
	1.	2002/0143024 A1	October 3, 2002	Murugesan et al.	514	258.1	December 14, 2000		
			FOREIGN I	PATENT DOCUMENTS					
		Document No.	Date	Country	Class	Sub-Class	Translation		
	2.	EP 0713875	March 21, 2001	EP					
	3.	EP 0749964	October 14, 2001	EP			\		
	4.	GB 2295616 A	June 5, 1996	GB					
	5.	WO 95/26957	October 12,1995	WIPO			· · · · · · ·		
	6.	WO 98/13366	April 2, 1998	WIPO					
	7.	WO 00/01389	January 13, 2000	WIPO					
	8.	WO 01/44239	June 21, 2001	WIPO					
	9.	WO 03/051870	June 26, 2003	WIPO					
	10.	WO 2004/007472	January 22, 2004	WIPO					
	<u> </u>						<b>V</b>		
				•			•		
	1			ing Author, Title, Date, Pe			20. 7.1.11.6		
	11.			accession no. 2000:34745,					
		Squibb Bo.: "Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotension II and							
	12.	endothelin receptor antagonists" & WO, A1, 2000001389, 20000113, see compound with CAS RN 25475-89-9							
	12.	STN International, File HCAPLUS, HCAPLUS accession no. 1982:484681: Document no. 97:84681, Kivman, G. Ya. et al: "Penetration of sulfanilamides into inflammatory foci"; & KhimFarm. Zh. (1982), 16(6), 665-7							
	13.			accession no. 1966:84579,					
	15.			titration of several sulfonam					
		series"; & Arch. Pharm				pyrrauzine, j	byruzine, una pyruzoro		
	<u> </u>	, , , , , , , , , , , , , , , , , , , ,	(), (-),			-			
						-			
	ļ								
	<u> </u>								
	<u> </u>								
	ļ								
	<del> </del>			-					
	<del>                                     </del>		<del></del>		<del> </del>		<del></del>		
	<del>                                     </del>				·····				
	<del> </del>								
Examiner	L		Data Co	onsidered					
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in									
conformance and not considered. Include copy of this form with next communication to applicant.									